Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834210 | 0.93 | SLC29A1 (0.43) | SLC29A1ADORA3ADORA2BADORA1P2RY12 | |
| SCHEMBL6835937 | 0.93 | SLC29A1 (0.43) | SLC29A1ADORA3ADORA2BADORA1P2RY12 | |
| SCHEMBL6892237 | 0.93 | SLC29A1 (0.45) | SLC29A1ADORA3ADORA2BADORA1P2RY12 | |
| SCHEMBL8380398 | 0.81 | SLC29A1 (0.49) | SLC29A1ADORA3ADORA2BADORA1P2RY12 | |
| SCHEMBL6892233 | 0.80 | TAS1R3 (0.41) | SLC29A1ADORA3ADORA2BADORA1 | |
| SCHEMBL7040477 | 0.79 | SLC29A1 (0.57) | SLC29A1ADORA3P2RY12 | |
| SCHEMBL6890238 | 0.77 | POLB (0.39) | — | |
| SCHEMBL6896046 | 0.76 | SLC29A1 (0.41) | SLC29A1ADORA3ADORA2BADORA1 | |
| SCHEMBL7035979 | 0.76 | SLC29A1 (0.57) | SLC29A1ADORA3ADORA1 | |
| SCHEMBL9446435 | 0.76 | SLC29A1 (0.57) | SLC29A1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750335-B2 | NUCLEOSIDE FOR USE IN THE GENERATION OF PREFERENTIAL OLIGONUCEOTIDES | NIGU CHEMIE GMBH (DE) | 2004-06-15 | — | — | US | disclosed |
| EP-1224198-B1 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS | NIGU CHEMIE GMBH (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020146737-A1 | Nucleoside derivatives with photolabile protective groups | NIGU CHEMIE GMBH (DE) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020146737-A1 | Nucleoside derivatives with photolabile protective groups | XRN2, XPA, NSUN2 | SLC29A1 469/4885ADORA3 285/4885ADORA2B 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.